Orforglipron + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity
Conditions
Obesity, Overweight
Trial Timeline
Nov 18, 2024 → Mar 1, 2027
NCT ID
NCT06672549About Orforglipron + Placebo
Orforglipron + Placebo is a phase 3 stage product being developed by Eli Lilly for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06672549. Target conditions include Obesity, Overweight.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07241390 | Phase 3 | Recruiting |
| NCT07223593 | Phase 3 | Recruiting |
| NCT07202884 | Phase 3 | Recruiting |
| NCT07153471 | Phase 3 | Recruiting |
| NCT06972472 | Phase 3 | Recruiting |
| NCT06972459 | Phase 3 | Recruiting |
| NCT06993792 | Phase 3 | Recruiting |
| NCT06952530 | Phase 3 | Recruiting |
| NCT06948435 | Phase 3 | Recruiting |
| NCT06948422 | Phase 3 | Recruiting |
| NCT06824051 | Phase 1 | Completed |
| NCT06672939 | Phase 3 | Recruiting |
| NCT06672549 | Phase 3 | Recruiting |
| NCT06649045 | Phase 3 | Active |
| NCT06584916 | Phase 3 | Completed |
| NCT06109311 | Phase 3 | Completed |
| NCT05971940 | Phase 3 | Completed |
| NCT05931380 | Phase 3 | Completed |
| NCT05869903 | Phase 3 | Active |
| NCT05872620 | Phase 3 | Completed |
Competing Products
20 competing products in Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 52 |
| MK0557 | Merck | Phase 3 | 77 |
| AMG 786 | Amgen | Phase 1 | 32 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| Tirzepatide | Eli Lilly | Phase 2 | 52 |
| exenatide + Placebo | Eli Lilly | Approved | 85 |
| Brenipatide | Eli Lilly | Phase 1 | 33 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 28 |
| PG-102 | Rani Therapeutics | Phase 1 | 25 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 33 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 33 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 44 |
| Tirzepatide | Eli Lilly | Approved | 85 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 23 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 85 |
| Micafungin | Astellas Pharma | Approved | 85 |